Investors
Investor Relations
Corporate Profile
PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat cardiovascular diseases. Our lead product candidate is bentracimab (PB2452), a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB6440, a highly selective aldosterone synthase inhibitor in development for treatment resistant hypertension and potentially other cardio-renal indications.
Stock
Apr 2, 2022 9:26 AM EDT
Data Provided by Refinitiv. Minimum 15 minutes delayed.